ArticlePharmacoEconomics - open2023

A Cross-Indication Budget Impact Model of Secukinumab for the Treatment of Psoriasis, Psoriatic Arthritis, Ankylosing Spondylitis and Non-radiographic Axial Spondyloarthritis in Italy.

Paolo Angelo Cortesi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.